Astellas Pharma gains rights to symbicort in Japan in a deal with AstraZeneca
스크롤 이동 상태바
Astellas Pharma gains rights to symbicort in Japan in a deal with AstraZeneca
기자명
메디칼라이터팀
입력 2009.08.06 00:00
수정 2009.08.06 08:30
댓글 0
AstraZeneca Plc. sold some rights to its asthma drug Symbicort [budesonide and formoterol fumarate dihydrate] in Japan to Astellas Pharma Inc. for a one-time payment of three billion yen with up to 5.5 billion yen if certain sales quotas are met.